Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer closes Topsun deal

This article was originally published in The Tan Sheet

Executive Summary

Bayer closes its $157 million acquisition of part of Topsun Science & Technology Qidong Gaitianli Pharmaceutical Co.'s OTC assets, the firms say July 3. Bayer gained the Chinese firm compound pseudoephedrine hydrochloride tablets, which analysts expect to produce $48 million in sales this year. Bayer will also pay a $24 million bonus at the end of the year as part of the deal (1"The Tan Sheet" Oct. 30, 2006, p. 9)...

You may also be interested in...



China's Aging Population Spurs OTC Sales, Looks For More Options

China's over-the-counter drug market grew more than 30 percent from 2007 to 2009 to more than RMB 90 billion ($13 billion), according to health care market intelligence provider IMS Health

Bayer Increases Chinese Presence With Topsun Cough/Cold Buy

Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25

TTS Pharma Wants To Bring First Legal CBD Oil To The UK

TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.

Topics

UsernamePublicRestriction

Register

PS101836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel